Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Share-based Compensation (2019 - 2025)

Historic Share-based Compensation for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $15.8 million.

  • Kymera Therapeutics' Share-based Compensation rose 602.52% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.2 million, marking a year-over-year increase of 1369.96%. This contributed to the annual value of $55.0 million for FY2024, which is 2758.48% up from last year.
  • Per Kymera Therapeutics' latest filing, its Share-based Compensation stood at $15.8 million for Q3 2025, which was up 602.52% from $15.4 million recorded in Q2 2025.
  • Over the past 5 years, Kymera Therapeutics' Share-based Compensation peaked at $15.8 million during Q3 2025, and registered a low of $3.2 million during Q1 2021.
  • Moreover, its 5-year median value for Share-based Compensation was $10.9 million (2023), whereas its average is $10.7 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first soared by 76234.94% in 2021, then skyrocketed by 266.19% in 2022.
  • Over the past 5 years, Kymera Therapeutics' Share-based Compensation (Quarter) stood at $8.7 million in 2021, then grew by 2.66% to $8.9 million in 2022, then rose by 22.33% to $10.9 million in 2023, then grew by 26.62% to $13.8 million in 2024, then increased by 14.52% to $15.8 million in 2025.
  • Its Share-based Compensation was $15.8 million in Q3 2025, compared to $15.4 million in Q2 2025 and $14.2 million in Q1 2025.